Skip to main content
SpringerLink
Log in

Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer

  • First International Symposium on Treatment of Liver Cancer Kobe, Japan, 15–16 November 1987 Session 2: Chemotherapy, Immunotherapy and Radiotherapy
  • Mitomycin C, 5-FU, OK 432 Advanced Liver Cancer, Combination Chemotherapy, FAM
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

We have previously reported that the combination of mitomycin C, carboquone, 5-fluorouracil and OK-432, including the intra-arterial administration of mitomycin C and carboquone (MQ-F-OK therapy), was effective in the treatment of advanced liver cancer. The Cooperative Study Group conducted a controlled study on MQ-F-OK therapy and the combination of mitomycin C, 5-fluorouracil and doxorubicin, including the intra-arterial administration of mitomycin C and doxorubicin (FAM therapy), against advanced liver cancer. Forty patients with advanced primary or secondary liver cancer were enrolled in this study and randomized into the MQ-F-OK group and the FAM group. Seventeen of the 21 cases in the MQ-F-OK group and 16 of the 19 cases in the FAM group were eligible for response evaluation in accordance with the criteria of the Japan Society for Cancer Therapy. There was no significant difference in the patient characteristics between the two groups. Three cases in the MQ-F-OK group and two in the FAM group showed partial response. There was, however, no significant difference in the response rates and the prolongation of life between the two groups. As for the side-effects, only anemia was observed more frequently in the FAM group than in the MQ-F-OK group. In conclusion, we could not preferentially recommend either MQ-F-OK therapy or FAM therapy for advanced liver cancer. The performance status of the patient was one of the most important factors in the treatment of advanced liver cancer because patients with poor performance status showed poorer results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Al-Idrissi HY, Ibrahim EM, Abdel Satir A, Satti MB, Al-Kasem S, Al-Qurain A (1985) Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin C. Hepatogastoroenterology 32: 8–10

    Google Scholar 

  2. Aoyama M, Hirose H, Adachi N, Udo K, Oshima K, Kobayashi S (1981) Comparison of combination therapy of 5-fluorouracil, mitomycin C and adriamycin (FAM) and mitomycia C, 5-fluorouracil, and cytosine arabinoside (MFC) for advanced gastric cancer. Jpn J Cancer Chemother 8: 757–762

    Google Scholar 

  3. Falk RE, Greig P, Makowaka L, et al. (1982) Intermittent percutaneous infusion into the hepatic artery of cytotoxic drugs for hepatic tumours. Can J Surg 25: 47–50

    Google Scholar 

  4. Friedman MA, Vorbelding PA, Cassidy MJ, et al. (1979) Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole liver irradiation: a Northern California Oncology Group Study. Cancer Treat Rep 63: 1885–1888

    Google Scholar 

  5. Heim N, Epelbaum R, Cohen Y, Robinson E (1984) Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, adrimycin (doxorubicin), and mitomycin C (modified FAM). Cancer 54: 1999–2002

    Google Scholar 

  6. Japan Society for Cancer Therapy (1986) J Jpn Soc Cancer Ther 21: 929–942

    Google Scholar 

  7. Kubo Y, Shirai K, Hirai H, Abe M (1986) Present status of chemotherapy on hepatocellular carcinoma. Saishin Igaku 41: 594–599

    Google Scholar 

  8. MacDonald JS, Schein PS, Woolley PV, et al. (1980) 5-Fluorouracil, doxorubicin, and mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536

    Google Scholar 

  9. Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. Cancer 51: 206–210

    Google Scholar 

  10. Miyamoto H, Ogawa M, Inagaki J, et al. (1982) Arterial infusion of combination chemotherapy using adriamycin and mitomycin C for hepatoma and metastatic tumors of the liver. Jpn J Cancer Chemother 9: 1955–1960

    Google Scholar 

  11. Morstyn G, Bunn PA, Ihde DC, Eddy JL, Cohen MH, Minna JD (1983) Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. Am J Clin Oncol 6: 547–551

    Google Scholar 

  12. Natsu-ume Sasaki S, Ryoyama K, Koshimura S, Migita S (1976) Studies on the properties of a streptococcal preparation OK-432 (NSC-B-116209) as an immunopotentiator. Jpn J Exp Med 46: 123–133

    Google Scholar 

  13. Ogawa M, Ito Y (1986) Chemotherapy for hepatoma. Sogo Rinsho 35: 1937–1939

    Google Scholar 

  14. Okamoto H, Shoin S, Koshimura S, et al. (1967) Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci (a review). Jpn J Microbiol 11: 323–336

    Google Scholar 

  15. Sakata Y (1978) Effect of new trial MQF combination therapy against ascitic hepatic tumor cells- AH 7974, AH 130. Proc Jpn Cancer Ass 37th Annu Meet 1978, Tokyo, p 624

  16. Sakata Y, Nishimura S, Komatsu Y, et al. (1979) The effect of the combination chemotherapy of mitomycin C, carboquone and 5-fluorouracil on the life span of the Hirosaki tetraploid sarcoma. Jpn J Cancer Clin 25: 1481–1482

    Google Scholar 

  17. Sakata Y, Sugawara K, Komatsu Y, Yoshida Y, Nishimura S, Kikuchi H (1979) Combination Chemotherapy of mitomycin C, carboquone, 5-fluorouracil and OK-432 for inoperable gastric cancer. J Jpn Soc Cancer Ther 14: 978–987

    Google Scholar 

  18. Sakata Y, Yoshida Y, Komatsu Y, et al. (1982) Studies on MQF-OK therapy against inoperable gastric cancer-Comparison with MFC therapy. Jpn J Cancer Chemother 9: 109–115

    Google Scholar 

  19. Sakata Y, Tsushima K, Suzuki H, et al. (1987) Prognostic factors prior to chemotherapy in patients with inoperable liver cancer. Hirosaki Med J 39: 395–399

    Google Scholar 

  20. Tanikawa K, Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Abe M (1985) One-shot therapy and transcatheter arterial embolization (TAE) therapy for unresectable hepatocellular carcinoma. Jpn J Cancer Chemother 12: 1930–1937

    Google Scholar 

  21. Tsushima K, Sakata Y, Suzuki H, et al. (1984) The combination chemotherapy of mitomycin C, carboquone, 5-fluorouracil and OK-432 against inoperable liver cancer — including the method of intraarterial administration of MMC and CQ. Hirosaki Med J 36: 590–599

    Google Scholar 

  22. Ueoka H, Kuroda S, Ohnoshi T, et al. (1984) Intraarterial adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma. Jpn J Cancer Chemother 11: 2579–2584

    Google Scholar 

  23. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401

    Google Scholar 

  24. Wils J, Schalngen J, Naus A (1986) Phase II of hepatic artery Infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma. Recent Results Cancer Res 100: 157–162

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hirosaki Cooperative Study Group of Cancer Chemotherapy, First Department of Internal Medicine, Hirosaki University School of Medicine, 036, Hirosaki, Japan

    Yuh Sakata, Yoshihiko Komatsu, Shinya Takagi, Soh Saitoh, Tohru Itoh, Hidekazu Suzuki, Kenichi Tsushima, Daisuke Sasaki & Yutaka Yoshida

Authors
  1. Yuh Sakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiko Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinya Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soh Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tohru Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hidekazu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenichi Tsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daisuke Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yutaka Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sakata, Y., Komatsu, Y., Takagi, S. et al. Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer. Cancer Chemother. Pharmacol. 23 (Suppl 1), S9–S12 (1989). https://doi.org/10.1007/BF00647230

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00647230

Keywords

Search

Navigation